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ABSTRACT 
 
Importance: Evidence are accumulating that repeated mild traumatic brain injury 
(mTBI) incidents can lead to persistent, long-term debilitating symptoms, and in 
some cases a progressive neurodegenerative condition referred to as chronic 
traumatic encephalopathy (CTE). However, there are no objective tools to examine 
to which degree persistent symptoms after mTBI are due to neuronal injury.  
 
Objective: To determine whether persistent symptoms after mTBI are associated 
with brain injury as evaluated by cerebrospinal fluid (CSF) biochemical markers for 
axonal damage and other aspects of central nervous system (CNS) injury. 
 
Design, settings, and participants: A multicenter cross-sectional study involving 
professional Swedish ice hockey players who have had repeated mTBI, and post-
concussion symptoms for over 3 months, and fulfilling the criteria for post-
concussion syndrome (PCS) according to the Diagnostic and Statistical Manual of 
Mental Disorder-IV, as well as neurologically healthy controls. The participants were 
enrolled between January 2014 and February 2016. All players were also assessed 
with Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and magnetic 
resonance imaging.  
 
Main Outcomes and Measures: Neurofilament light protein (NF-L), total-tau (T-
tau), glial fibrillary acidic protein (GFAp), amyloid-β (Aβ1-42), phosphorylated tau 
(P-tau), and neurogranin (Ng) concentrations in CSF.  
 
Results: A total of 31 participants (16 with PCS, and 15 controls) were assessed. Of 
16 players with PCS, nine had PCS symptoms  > 1 year, while the remaining seven 
returned to play within a year. NF-L were significantly increased in players with PCS 
> 1 year compared with players whose PCS resolved within 1 year, as well as 
controls (P = .035 and P = .021, respectively). Furthermore, NF-L concentrations 
correlated with RPQ scores and lifetime concussion event (ρ = 0.58, P = .020 and ρ = 
0.52, P = .040, respectively). Overall, players with PCS had significantly lower CSF 
Aβ1-42 levels compared to controls (P = .048).  
 
Conclusions and Relevance: Increased CSF NF-L and reduced Aβ1-42 were 
observed in PCS, suggestive of axonal white matter injury and amyloid deposition. 
Measurement of these biomarkers may be an objective tool to assess the degree of 
CNS injury in individuals with PCS, and to distinguish individuals who are at risk of 
developing CTE.  
 
Introduction 
Traumatic brain injury (TBI) represents a leading cause of mortality and morbidity 
worldwide, with 1.6–3.6 million sports-related TBIs occurring annually alone in the 
Unites States and additional large numbers occurring in civilian and military 
personnel.1 Mild TBI (mTBI), commonly also referred to as concussion in the 
literature, is a type of mTBI that is caused by rapid acceleration, deceleration and 
rotational forces to the head, which cause the brain to deform, resulting in stretching 
of individual neurons, glial cells and blood vessels.2  
 
Symptoms of mTBI usually resolve within days to weeks, but in 10-15% of 
individuals neurological symptoms persist for more than three months.3 The presence 
of neurological symptoms lasting more than three months in individuals who have 
suffered from mTBI is referred to as post-concussion syndrome (PCS).3 A proportion 
of individuals exposed for repeated mTBI episodes may develop a progressive 
neurodegenerative condition referred to as chronic traumatic encephalopathy 
(CTE).4,5 CTE shares similar histopathological changes with other neurodegenerative 
disorders, in particular Alzheimer’s disease (AD), including hyperphosphorylation of 
tau protein in neurofibrillary tangles and in a proportion of cases also deposition of 
amyloid β (Aβ) in diffuse plaques.6,7  
 
The relationship between repeated mTBIs and development of PCS is poorly 
understood, specifically to which degree such long-lasting symptoms are due to 
neuronal damage, and to which degree psychogenic or psychosocial mechanisms 
contribute. Notably, there are no objective biomarkers to quantify neuronal damage 
or other types of central nervous pathology in individuals with PCS. At present, PCS 
diagnosis is mainly based on self-reporting clinical symptoms, while CTE diagnosis 
can only be made post-mortem.4,5,8,9 Further, the relation between PCS and future 
development of CTE is unknown.  
 
The cerebrospinal fluid (CSF) is in direct contact with the brain parenchyma and is a 
suitable biofluid to monitor biochemical changes in the central nervous system 
(CNS). CSF biomarkers reflecting amyloid and tau pathology have been validated 
extensively in the context of AD.10-14 Recently, independent reports have shown that 
neurodegenerative disorders, mainly AD, also are associated with increased levels of 
CSF neurogranin (Ng), which reflect synaptic degeneration and loss,15-17 as well as 
increased CSF neurofilament light protein (NF-L), reflecting injury to large-caliber 
myelinated axons in the white matter.18,19  
 
Considering that CTE shares many neuropathological changes with AD, we 
hypothesized that PCS would also display similar pathophysiology, at least in CSF. 
We specifically tested the following hypotheses: i) PCS is associated with axonal 
injury and astrogliosis, as reflected by increased CSF concentrations of the axonal 
proteins total-tau (T-tau) and NF-L, as well as the astroglial protein glial fibrillary 
acid protein (GFAp), and ii) PCS is associated with increased amyloid burden and 
tau pathology, as well as synaptic loss, as reflected by altered CSF concentrations of 
the 42 amino acid variant of Aβ (Aβ1-42), phosphorylated tau (P-tau), and the 
synaptic biomarker Ng.  
 
Methods 
Study population 
In this multicenter cross-sectional study, we enrolled 16 male professional ice 
hockey players with prolonged post-concussive symptoms for over three months and 
15 neurologically healthy controls between January 2014 and February 2016. The 
study was approved by the Ethics Committee for Medical Research at the University 
of Gothenburg, Sweden. Written informed consent was obtained from all 
participants. 
 
Selection of participants 
The diagnosis of concussion was made according to the latest diagnostic guidelines 
on sports-related concussion and players with concussion were managed according to 
these guidelines.20,21 The diagnosis of PCS was based on Diagnostic and Statistical 
Manual of Mental Disorder-IV (DSM- IV) criteria.22 The inclusion criteria were: 1) 
persistent post-concussion symptoms for more than three months following mTBI, 2) 
no contraindications to lumbar puncture (LP) (decreased platelet count (< 50 x 
109/L), focal neurologic sign, papilledema, reduced consciousness, infection at 
puncture site), and 3) no evidence of structural damage on conventional magnetic 
resonance imaging (T1/T2 and flair).  
 
The inclusion criteria for control subjects were: 1) age > 18 years, 2) no history of 
known head trauma, 3) no history of neurological or psychological condition, and 4) 
no contradictions to LP as stated above.  
 
At inclusion, the participants underwent neuropsychological assessment with 
Rivermead Post Concussion Questionnaire (RPQ)23, and the PCS group was also 
followed with repeated RPQ assessment at the end of the study. One of the players 
agreed to undergo repeated LPs at inclusion, 11 months, 17 months and 23 months 
after the injury.  
 
Biochemical procedures 
CSF was collected in polypropylene tubes by LP through the L3-4 or L4-5 
interspace. All CSF samples were stored at −80 °C pending analysis. The participants 
were examined physically and neurologically before LP. All were healthy and 
showed no signs of focal neurologic injury.  
 
CSF NF-L concentrations were measured using a commercial ELISA (NF-light® 
ELISA, Uman Diagnostics, Umeå, Sweden) as described previously.24 CSF GFAp 
concentrations were measured using a previously described in-house ELISA 
procedure.25 CSF concentrations of Aβ1-42, T-tau, and P-tau were measured with 
INNOTEST (Fujirebio Diagnostics, Japan). CSF Ng concentrations were measured 
using an in-house developed ELISA employing two monoclonal antibodies. In brief, 
the monoclonal antibodies were developed by immunizing 8-week-old Balb/c mice 
with the KLH-conjugated peptide Ng52–75 or Ng 63-75 (Caslo, ApS Denmark) in 
complete Freund’s adjuvant (Sigma). Ng22 (with the epitope 63-75) and Ng2 (with 
the epitope 52-63) were selected for the final assay set up and the method protocol 
was developed as follows. Nunc maxisorp 96-well microliter plates were coated with 
3g/mL of Ng22 in bicarbonate buffer (pH 9.6) and incubated over night at + 4C. 
After washing with PBS (0.01 M phosphate buffer, 0.14 M NaCl, pH 7.4)-Tween 
(0.05%) the plates were blocked with 200 L PBS-Tween (0.05%) with 1% BSA. 
After the second wash, 100 L of calibrators (full length 1-78 neurogranin (Caslo)), 
quality control CSF samples and CSF samples was loaded in each well and incubated 
over night at + 4C. After washing, 100 L of the detection antibody, biotinylated 
Ng2, diluted to 2.7g/mL in PBS-Tween (0.05% BSA) with 1% BSA, was incubated 
at room temperature for 1 hour, shaking. After washing, 100L Enhanced 
Streptavidin-HRP (Kem-En-Tec Diagnostics) was added in a 1:20000 dilution in 
PBS-Tween (0.05%) with 1% BSA and incubated for 30 min. After a final wash, 100 
L of substrate (TMB One Substrate, Kem-En-Tec Diagnostics) was incubated in the 
dark for 20 minutes and the reaction was quenched with 100 L 2 M H2SO4. The 
plate was read at 450 nm  (reference wavelength 650 nm) using an ELISA plate 
reader (Vmax, Molecular Devices, USA) and the calibration curve was plotted using 
a 4-parameter curve and calculations were made using SoftMax. The assay ranged 
between 6400 pg/mL and 50 pg/mL, where 50 pg/mL was set as the limit of 
quantification. Within and between plate coefficients of variability were < 5% and < 
13%, respectively.     
 
All samples were analyzed at the same time using the same batch of reagents by 
board-certified laboratory technicians who were blind to clinical information.  
 
Statistical analysis 
For the PCS versus controls comparison, the Mann-Whitney U test and independent 
sample t tests were used. Dunn’s correction was performed for all multiple 
comparisons. The Spearman’s rank correlation coefficient (rs) was used for analyses 
of correlation between changes in various biomarker levels and lifetime concussion 
event, as well as RPQ score. All tests were two-sided and statistical significance was 
determined at P < .05. All statistical calculations were performed using GraphPad 
Prism 6.0 (GraphPad Inc., San Diego, CA). 
 
 
Results 
Characteristics of the subjects 
Sixteen male players with PCS (median age, 31 years; range, 22-53) and 15 male 
neurologically healthy controls (median age, 25 years; range, 21-35) were enrolled 
between January 2014 and February 2016 (Table 1). Nine of the 16 players had 
persistent PCS symptoms for more than one year and retired from the game, while 
seven players returned to the game within one year from the injury.  
 
Axonal white matter damage in players with persistent PCS 
CSF concentrations of NF-L were increased in the PCS group as compared with the 
control group, but the increase did not reach statistical significance (Figure 1A). 
However, the concentrations of NF-L were significantly higher in the subgroup of 
players with PCS > 1 year vs. PCS < year (P = .035), as well as compared to the 
control group (P = .021) (Figure D). No significant differences were observed in the 
concentrations of T-tau or GFAp (Figure 1B,C, and E).  
 
Emerging CSF amyloid pathology in PCS 
CSF concentration of Aβ1-42 was significantly (P = .048) lower in the PCS group as 
compared to controls (P = .048) (Figure 2A). The subgroup of players with PCS > 1 
year had lower Aβ1-42 concentrations compared with players whose symptoms 
resolved within 1 year (P = .091), although the change was not statistically 
significant after correcting for multiple comparisons (Figure 2D). There was a trend 
towards lower concentrations of P-tau and Ng at group level, the differences were 
not significant though (Figure 2B, C, and F).  
 
Reduced CSF Aβ1-42, and increased Ng and NF-L over time 
Mean CSF NF-L concentration remained more than 2-fold increased compared to the 
mean of the controls in one of the player who underwent repeated lumbar punctures 
(Figure 3A). In addition, the player displayed reduced concentrations of Aβ1-42 
compared to the controls, while the concentrations of Ng were increased (Figure 3B) 
at all sampling time points. There was also a trend toward higher concentrations of 
CSF P-tau compared to controls (Figure 3B). The concentrations of other measured 
biomarkers were essentially unchanged (Figure 3B).  
 
CSF NF-L correlated with symptom severity in PCS 
As expected, the PCS group had higher RPQ score (median, 22; range (8-35) 
compared to the controls (median, 0; range, (0-0), P < .0001). CSF NF-L 
concentrations correlated with RPQ scores (ρ = 0.58, P = .020) (Figure 4A). There 
was no significant relationship between the concentrations of other measured 
biomarkers and RPQ (Figure 4B-F).   
 
CSF NF-L and P-tau correlate with lifetime concussion event 
CSF NF-L correlated with lifetime concussion event (ρ = 0.52, P = .040) (Figure 
5A). There was also a significant correlation between CSF P-tau and lifetime 
concussions (ρ = 0.55, P = .030) (Figure 5E). No significant relationships were 
observed between the lifetime concussion events and concentrations of the other 
biomarkers in the study (Figure 5B-D and F). 
 
Discussion 
 
Symptoms of mTBI usually resolve within days to weeks.3 However, a subgroup of 
individuals with mTBI, mainly repeated mTBI, display persistent physical, cognitive, 
and behavioral impairment for months, referred to as PCS.3 The relation between 
PCS and development of future CTE is unknown. Thus, improved methods of 
characterizing neurodegenerative processes triggered by repeated mTBI, and 
identifying individuals at risk of developing PCS or progressive neurodegeneration 
are needed. To our knowledge, this is the first study to investigate CSF biomarkers 
reflecting axonal white matter injury, amyloid burden, tau pathology, and synaptic 
loss in professional ice hockey players who have suffered repeated mTBI and 
fulfilled the criteria for PCS. We found that i) a subgroup of individuals with PCS 
(those with chronic symptoms forcing them to retire) displayed increased 
concentrations of CSF NF-L compared with those whose PCS resolved within one 
year, as well as controls, ii) CSF concentrations of NF-L correlated with RPQ scores 
and lifetime concussion events, iii) overall, the PCS group had lower CSF Aβ1-42 
concentrations compared with controls, and iv) there were no PCS-related changes in 
CSF T-tau, GFAp and Ng concentrations.  
 
NF-L is a structural protein that is highly expressed in the large-caliber myelinated 
subcortical axons of the white matter.18,19 The findings that NF-L is elevated in CSF 
of professional athletes with PCS, and CSF concentrations of NF-L correlated with 
RPQ scores, add support for the hypothesis that axonal white matter injury is a 
primary determinant of outcome following TBI.26-28 Furthermore, NF-L 
concentrations correlated with lifetime concussion event in this study. This result is 
also consistent with earlier studies on amateur boxers with repeated trauma to the 
head, where the levels of NF-L in CSF increased after bouts, even without 
knockouts.29,30 Additionally, a case study on a boxer with mTBI leading to a knock-
out showed increased CSF NF-L levels over many months following the trauma.31 
Taken together, the findings of this study support the hypothesis that repetitive mTBI 
may lead to chronic axonal white matter injury. CSF NF-L correlates with plasma 
NF-L,(Ref: Gisslen M et al., EBioMed 2015 eller 2016; Kuhle 2016 CCLM) which 
suggests that this marker could be more broadly applied in future mTBI and PCS 
studies. 
 
Tau is a normal axonal protein that is responsible for microtubule assembly and 
stability, and mainly expressed in unmyelinated cortical axons.11 In this study, the 
concentration of CSF T-tau was unchanged. Considering the pathophysiology of 
mTBI, it is plausible to assume that shorter unmyelinated axons, which do not travel 
long distance, may only be locally teared as a result of the acceleration and 
deceleration. Indirectly, the unaltered T-tau levels further support the hypothesis that 
TBI mainly injures long axons.  
 
Evidence suggests that athletes who have been exposed to repetitive head trauma are 
at increased risk of developing neurodegenerative changes such as tau pathology and 
Aβ deposition.4,5,8,9 Numerous studies have shown that reduced CSF Aβ1-42 levels 
correlate tightly with positive amyloid PET finding32, and a recent study also suggest 
that the reduction in CSF Aβ1-42 may be an earlier indicator of cerebral β-amyloid 
deposition than amyloid PET.33 The finding that CSF Aβ1-42 was lower in players 
with PCS compared to controls, and the lowest levels of Aβ1-42 were observed in 
players with PCS > 1year, who were also forced to retire are suggestive of potential 
early amyloid deposition following mTBI. Our findings are also consistent with post-
mortem studies of patients with mTBI, as well as a recent imaging study of patients 
with severe TBI.34 The exact mechanism of what triggers Aβ production is not fully 
understood. It has been suggested that axonal damage produced at the time of injury 
may act as an initial trigger for Aβ production and accumulation of amyloid 
pathology.35 Additionally, animal models and human autopsy studies provide 
evidence that Aβ is produced at the site of axonal injury shortly after TBI. 35  
 
Trauma to the axons may also cause hyperphosphorylation of tau protein and 
aggregation into neurofibrillary tangles, which is a histological feature of repetitive 
mTBI or CTE. However, in this study, the concentration of CSF P-tau remained 
statistically unchanged. A plausible assumption would be that tau pathology may 
appear at a later stage or that tau pathology is not as widespread following mTBI or 
alternatively P-tau measured in CSF is not sensitive enough to reflect it. Despite the 
unchanged concentrations between the PCS and control group, P-tau correlated with 
the lifetime accumulated concussion score. However, given the modest sample size 
of this study, this should be interpreted with caution. Longitudinal studies with larger 
sample sizes and repeated lumbar puncture are needed to clarify any causal 
relationship between repetitive mTBI and hyperphosphorylation of tau. Such studies 
should also examine the concentrations of CSF Aβ42 and P-tau in the context of 
genotype, particularly APOE,36 which was not assessed here. 
 
Neurogranin is a post-synaptic protein, which has shown diagnostic utility for early 
symptomatic AD.15-17 In this study, the concentrations of Ng were essentially 
unaltered in the PCS group. However, in one of the players with persistent PCS who 
underwent repeated LPs, the mean levels of Ng remained up to 2-fold elevated 
compared with mean of the control group. It is plausible to assume that, post-
synaptic loss may only be evident in individuals with severe PCS.  
 
In conclusion, increased CSF NF-L and reduced Aβ1-42 was observed in PCS, 
suggestive of axonal white matter injury and amyloid deposition. Measurement of 
these biomarkers may be an objective tool to assess the degree of CNS injury in 
individuals with PCS, and to distinguish individuals who are at risk of developing 
CTE.  
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 
Figure legends 
Figure 1. CSF biomarkers reflecting axonal injury biomarkers 
 
Concentrations of neurofilament light (NF-L) protein were increased in post-
concussion syndrome (PCS) group vs. controls (A). There was no significant 
difference in the level of total-tau (T-tau) (B) and glial fibrillary acidic protein 
(GFAp) (C). Players with PCS > 1 year had increased concentration of NF-L 
compared with players whose PCS resolved within 1 year after injury, as well as 
controls (D). There was no significant difference in the levels of T-tau (E) and GFAp 
(F) at either group or subgroup level, as well as compared to controls. The p-values 
are corrected for multiple comparisons. One of the 15 control subjects had increased 
CSF NF-L concentration (1491 pg/mL) for unknown reasons and was excluded from 
further statistical analyses. Values are presented as medians; error bars indicate 
interquartile range.  
 
Figure 2. CSF biomarkers reflecting amyloid and tau pathology and synaptic 
loss 
 
Post-concussion syndrome (PCS) group had significantly (P = .048) lower amyloid-β 
1-42 (Aβ 1-42) than control group (A). Also, concentration of Aβ 1-42 (C) were 
lower in players with PCS > year vs. PCS < 1 year, however not significant (P = 
.091). There was no difference in the levels phosphorylated tau at either group (B) or 
subgroup level (D). There was also no significant difference in the concentrations of 
neurogranin at either group (C) or subgroup level (F). The p-values are corrected for 
multiple comparisons. Values are presented as medians; error bars indicate 
interquartile range.  
Figure 3. Longitudinal biomarker changes 
 
One of they players was followed with repeated lumbar punctures; 5, 11, 17 and 23 
months last concussion.  In this player the mean concentration of neurofilament light 
protein was elevated compared with the mean of the control group, and remained 
elevated over time, while the levels of total-tau and glial fibrillary acidic protein 
were unchanged (A). Mean concentrations of amyloid-β 1-42 were lower at two 
following time points compared with mean of the control group (B). Also, the mean 
concentration of neurogranin was elevated compared with the mean of the control 
group (B). Dashed lined indicate mean + standard deviation of the control group. 
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Figure 4. Relationship between biomarker levels and symptom severity 
Concentrations of neurofilament light protein correlated (ρ = 0.58, P = .020) with 
Rivermead Post-concussion Symptoms Questionnaire (RPQ) score (A). There was 
no significant correlation between any of the other biomarkers and RPQ score (B-F).  
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Figure 5. Relationship between biomarker concentrations and lifetime number 
of concussions 
Neurofilament light protein correlated (ρ = 0.52, P = .040) with lifetime concussion 
event (A). There was also a significant correlation between phosphorylated tau and 
lifetime concussion event (E). There was no significant relationship between the 
lifetime concussion event and other biomarkers in the study (B-D, and F). 
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Table 1. Demographic and clinical characteristics of participants at 
inclusiona 
Variable PCS  
(n = 16) 
Controls 
(n = 15) 
Age, year 31 (22-53) 25 (21-35) 
Sex, male No. (%) 16 (100) 11 (73) 
Time since last concussion, month  4 (3-144) 0 
Lifetime number of concussions  6 (2-20) 0 
Post-lumbar headache 2 4 
Total Rivermead Post-Concussion Symptoms 
Questionnaire score, range, 0-64 
22 (8-35) 0 (0-0) 
Abbreviations: PCS = post-concussion syndrome 
aAll continuous variable are shown as median (range) unless denoted otherwise. 
 
 
